Phase 3 Readout
WST: Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase III Clinical Trial Ev
June 9, 2026 · hrs-9231. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 9, 2026
- Company
- West Pharmaceutical Services Inc. (WST)
- Drug
- hrs-9231
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout
Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase III Clinical Trial Ev
- Drug
- hrs-9231
- Indication
- For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS)